Charles River has launched Accugenix Next Gen Sequencing for Bacterial Identification and Fungal Identification (Accugenix NGS), a new sequencing offering within the company’s Accugenix portfolio of microbial testing services. Charles River developed the new offering based on customer feedback and desire for reducing the time and cost needed to sequence and analyze samples.  
 
Accugenix NGS sequences millions of individual DNA fragments from a sample and offers a snapshot of the microbiome at that point in time, providing key information about microbial control. When investigating mixed species environments, it shares insights on microbial populations without the need for any culturing, thus reducing downtime and uncertainty, which is critical for manufacturing decisions, risk assessments and remediations.  
 
By collaborating with professionals, the platform answers client questions, provides more robust compliance capabilities and higher levels of control, while offering partnership with a global network of labs, bioinformaticians, and specialists who interpret results, and provide post-report support. 
 
This new offering builds upon Charles River’s existing Accugenix portfolio that spans 10 lab locations globally and offers clients with microbial identification and strain typing services.